Enlivex Therapeutics Ltd. (ENLV)

Market Cap	26.76M
Revenue (ttm)	n/a
Net Income (ttm)	-14.33M
Shares Out	23.69M
EPS (ttm)	-0.66
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	33,878
Open	1.110
Previous Close	1.120
Day's Range	1.110 - 1.160
52-Week Range	0.810 - 1.760
Beta	0.74
Analysts	Strong Buy
Price Target	10.00 (+784.96%)
Earnings Date	May 30, 2025

About ENLV

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 12, 1995
• Employees: 71
• Stock Exchange: NASDAQ
• Ticker Symbol: ENLV
• Website: https://www.enlivex.com

Analyst Summary

According to 2 analysts, the average rating for ENLV stock is "Strong Buy." The 12-month stock price target is $10.0, which is an increase of 784.96% from the latest price.

Price Target

$10.0

(784.96% upside)

Analyst Consensus: Strong Buy